New shot aims to tame sickle cell pain

NCT ID NCT07224360

Recruiting now Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called anumigilimab in 63 adults with sickle cell disease to see if it is safe. Participants get weekly injections for 64 weeks, starting with a low dose that increases to their personal maximum. The goal is to reduce painful crises, but people will still need ongoing care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia hereditary disease sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Center for Cancer and Blood Disorders
RECRUITING

Bethesda, Maryland, 20817, United States
Jacobi Medical Center
RECRUITING

The Bronx, New York, 10461, United States
Southern Specialty Research
RECRUITING

Flowood, Mississippi, 39232, United States
The Foundation for Sickle Cell Disease
RECRUITING

Hollywood, Florida, 33023-6703, United States
UAMS Medical Center
RECRUITING

Little Rock, Arkansas, 72202, United States